肺转移瘤动脉灌注化疗的途径选择

目的研究肺转移瘤动脉灌注化疗途径对疗效的影响。方法肺转移瘤患者随机分成两组:A组为支气管动脉灌注(BAI)组,15例患者共49个病灶;B组为支气管动脉灌注联合肺动脉灌注(PAI)组,20例患者65个病灶,分别行BAI和BAI PAI,在DSA分为有血供和无血供两种,疗效评价用WHO的评价标准。结果A组总有效率(CR PR)为65.3%(32/49);B组总有效率为61.5%(40/65),两组相比差异无统计学意义;A组的中位生存期为9个月;B组中位生存期为11.5个月,差异也无统计学意义。结论肺转移瘤动脉灌注化疗应以支气管动脉为主。

Bronchial arterial infusion versus bronchial combined pulmonary arterial infusion for pulmonary metastatic tumors

Objective To evaluate the pulmonary metastatic tumor response to different ways of transcatheter arterial infusion.Methods Thirty-five patients with pulmonary metastatic tumors were randomized divided into two groups:15 patients with 49 lesions treated with bronchial arterial infusion(BAI) and 20 patients with 65 lesions treated with bronchial arterial infusion(BAI)combined with pulmonary arterial infusion(PAI).The therapeutic reponse was assessed by the WHO evaluation criteria.Results The total effective rate(CR PR) of BAI was 65.3%(32/49),PAI BAI was 61.5%(40/65) showing no statistical difference.The median survival time of BAI was 9 mo,BAI PAI was 11.5 mo,demonstrating no statistical significance.Conclusions BAI should be the primary treatment for pulmonary metastatic tumor.